...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Sorry...
I think Deke and I are saying the same thing. I'm not clear on how IPO's work but one thing I noticed is this... The Corporation is authorized to issue an unlimited number of Common Shares and an unlimited number of Preferred Shares. As at the effective date of this Management Information Circular (the “Effective Date”), which is November 30, 2015, the Corporation has 98,892,045 Common Shares issued and outstanding and nil Preferred Shares issued and outstanding. So, when an IPO is done, wouldn't it be done under Zenith Capital Corp? If so I would think they wouldn't be doing that any time soon. It wouldn't be worth much until the royalties start coming in. Or...would they have to sell Zenith Epiginetics Ltd. entirely...or could they continue to separate it into more wholly owned subsidiaries and then do individual IPO's?? Apologies again...in previewing this msg I get no paragraph separations. Not sure what I'm doing wrong. Any tips much appreciated.
Share
New Message
Please login to post a reply